Homology Medicines, Inc. (0T6G.L)
USD 3.22
(-5.26%)
USD 3.22
(-5.26%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 44.05 Million USD | 72.47% |
| 2022 | 29.47 Million USD | 23.16% |
| 2021 | 23.93 Million USD | 54.99% |
| 2020 | 15.44 Million USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 16.24 Million USD | 16.86% |
| 2024 Q1 | 20.14 Million USD | 1428.6% |
| 2023 Q1 | 29.1 Million USD | -1.28% |
| 2023 Q3 | 28.33 Million USD | -1.34% |
| 2023 FY | 1.31 Million USD | -95.53% |
| 2023 Q4 | 1.31 Million USD | -95.35% |
| 2023 Q2 | 28.72 Million USD | -1.3% |
| 2022 Q3 | 29.82 Million USD | 24.29% |
| 2022 Q2 | 23.99 Million USD | 0.06% |
| 2022 Q1 | 23.98 Million USD | 0.2% |
| 2022 Q4 | 29.47 Million USD | -1.17% |
| 2022 FY | 29.47 Million USD | 23.16% |
| 2021 Q3 | 13.54 Million USD | -4.57% |
| 2021 Q4 | 23.93 Million USD | 76.75% |
| 2021 FY | 23.93 Million USD | 54.99% |
| 2021 Q2 | 14.18 Million USD | -4.26% |
| 2021 Q1 | 14.82 Million USD | 0.0% |
| 2020 FY | 15.44 Million USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -20.577% |
| Dynavax Technologies Corporation | 256.91 Million USD | 82.853% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -6.085% |
| Perrigo Company plc | 4.07 Billion USD | 98.918% |
| Illumina, Inc. | 2.26 Billion USD | 98.052% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.874% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -4305.4% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.539% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.69% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 74.646% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.37% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -63.223% |
| Waters Corporation | 2.35 Billion USD | 98.13% |
| Biogen Inc. | 7.33 Billion USD | 99.4% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -15.615% |
| Evolus, Inc. | 126.54 Million USD | 65.187% |
| Adicet Bio, Inc. | 17.7 Million USD | -148.85% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -2.055% |
| bluebird bio, Inc. | 330.32 Million USD | 86.663% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 91.856% |
| FibroGen, Inc. | 170.45 Million USD | 74.155% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.389% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -110.944% |
| Geron Corporation | 85.89 Million USD | 48.714% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 98.163% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 90.102% |
| Myriad Genetics, Inc. | 145 Million USD | 69.618% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -3396.349% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 61.807% |
| Zoetis Inc. | 6.8 Billion USD | 99.352% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -900.772% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 97.968% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 96.115% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 94.55% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -21.284% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 96.969% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 23.877% |
| Verastem, Inc. | 41.55 Million USD | -6.009% |
| Nektar Therapeutics | 230.4 Million USD | 80.879% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 76.362% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1333.116% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 96.846% |
| OPKO Health, Inc. | 326.56 Million USD | 86.51% |
| Exelixis, Inc. | 189.94 Million USD | 76.807% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 89.717% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -29074.834% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 68.171% |
| Imunon, Inc. | 1.13 Million USD | -3766.784% |
| Blueprint Medicines Corporation | 774.12 Million USD | 94.309% |
| Insmed Incorporated | 1.2 Billion USD | 96.341% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.062% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 22.696% |
| TG Therapeutics, Inc. | 110.79 Million USD | 60.238% |
| Incyte Corporation | 38.28 Million USD | -15.063% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 94.98% |